What takes place in the female germ cells and what makes it possible to create a new human being? These questions are the focal point of Karin Lykke-Hartmann's research. At Aarhus University she examines the genes that contribute to proper and complete maturation of the woman's egg.

Spun out of Karin Lykke-Hartmanns work at Aarhus University, Denmark, Notify builts upon a decade of world-class research into the activation of dormant follicles – a process that is pivotal for fertile eggs to mature.

Meet the Team

  • Karin Lykke-Hartmann, PhD

    Chief Executive Officer & Founder

    Professor in reproductive medicine at Aarhus University, Denmark, and an expert in reproductive science and translational medicine. Karin’s long and fervid interest in ovarian follicle development has resulted in an extensive international network and a widely acknowledged in-depth understanding of the molecular mechanisms underlying the transformation of an early dormant follicle into a mature and fertile egg.

  • Jean-Pierre Gotteland, PhD

    Chief Development Officer

    PhD in organic chemistry. More than 40 publications and 30 patents. Drug development expert with more than 30 years of experience pharmaceutical industry in various management roles moving projects from discovery up to registration and commercialization especially in the field of women’s reproductive health.

  • Joakim Sørensen, MBA

    Business Developer

    Joakim brings extensive experience in operations and business development of biotech startups. He has prior experience with successful startups helping to form and mature the companies for their Series A

  • Henrik Stage

    Financial Advisor

    International experience and a pragmatic business approach, in roles as CEO, CFO and Partner, created major changes and outstanding results in companies operating within biotech, manufacturing and FMCG. Former CFO of Santaris and CEO of Adcendo

  • Peter Mouritzen, MSc, MBA

    Director of Operations

    Double Master’s degrees in Pharmaceutical Engineering and Business Administration with a track record in operational excellence, fundraising, and venture building. Prior roles include Innovation Consultant at Innovayt A/S, and Head of Business Development and Business Operations Manager at Twelve Bio ApS. Notably, he co-led the successful sale of Twelve Bio ApS to Ensoma Inc and led the post-merger integration and expansion in Copenhagen.

  • Duc Tran, PhD

    Duc Tran brings over twenty five years of experience in drug discovery and drug development in working for big pharma companies (Sanofi-Aventis, Pfizer, Lundbeck) and start-ups (Preglem, Prexton Therapeutics, Step Pharma) in various disease areas encompassing cardiovascular, anti-infective, urology, epigenetics, CNS, rare disease and reproductive medicine, delivering a large number of projects into clinical development up to registration.

Board of Directors

  • Prof. Klaus Dugi, MD, PhD

    Chair, +ND Capital

    Klaus Dugi is currently CEO of Vandria and a Board member at AOBiome Therapeutics and Ferring Ventures. Since 2021, Klaus is also Chief Medical Advisor & Venture Partner at +ND Capital in Lausanne. Prior to this, he spent 18 years in pharmaceutical industry with Boehringer Ingelheim and Ferring Pharmaceuticals, mostly in leadership positions including more than 8 years as Chief Medical Officer.

  • Jacob Falck Hansen, PhD

    Board member, Lundbeckfonden BioCapital

    Jacob Falck Hansen is a Partner at Lundbeckfonden BioCapital. He has 15 years of experience from the pharmaceutical industry. Prior to joining the Lundbeck Foundation in 2022, he was head of corporate strategy at Novo Nordisk A/S. Jacob is a board member at Dysis Medical, a women’s health company, and a board observer at SNIPR Biome. He holds a MSc in Biochemistry and a PhD from the University of Copenhagen.

  • Henrik Stage

    Board Member, Notify Therapeutics

  • Gabriela Ecco, PhD

    Board Observer, +ND Capital

    Gabriela is a Senior Associate at +ND Capital’s European office. She holds a PhD in Biotechnology and Bioengineering from EPFL and has accumulated 15 years of experience in R&D in academia and industry in different areas of life sciences, developing products for molecular diagnostics in oncology and publishing in top-tier academic journals.

  • Kevin Dalgaard, PhD

    Board Observer, Lundbeckfonden BioCapital

    Kevin is a Principal at Lundbeckfonden BioCapital. Prior to this, he was with Boehringer Ingelheim where he as a Strategic Partner in Business Development successfully led global licensing activities within Cardiometabolism and Retinal Health.

    Kevin holds an M.Sc. in Biochemistry from the University of Copenhagen, and a Ph.D. from Max Planck Institute.

  • Sanne Brun Jensen, PhD

    Board Observer, BioInnovation Institute

    Sanne Brun Jensen is a Business Development Associate at the BioInnovation Institute Foundation (BII). Sanne holds a Ph.D. from Department of Immunology and Microbiology, University of Copenhagen, and an M.Sc. in Human Biology.

Our investors